Ligand Pharmaceuticals | LGND - Assets


Ligand Pharmaceuticals reported $2.24B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
Amgen USD 96.05B 409M Sep/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 1.74B 373.76M Sep/2026
Baxter International USD 19.41B 377M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Enviri Corporation USD 2.7B 4.56M Mar/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Glaxosmithkline GBP 71.7B 8.83B Sep/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Insmed USD 2.23B 123.49M Sep/2026
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
MacroGenics USD 318.68M 26.72M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Pacira USD 34.68B 33.44B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Veracyte USD 1.57B 86.89M Sep/2026